Neupulse Wrist Device Offers Relief for Tourette's Syndrome Patients
A novel electrical stimulation device helps patients manage tic symptoms with immediate effect.
1Innovative Neurological Relief
Researchers at the University of Nottingham developed a wrist-worn device designed to mitigate Tourette's syndrome symptoms. By delivering rhythmic electrical pulses to the median nerve, the technology alters brain activity related to movement control. Clinical trials indicate that this stimulation can significantly reduce the frequency and intensity of involuntary tics.
2Patient Experiences and Impact
Fifteen-year-old Katie, who suffered from severe tics since age seven, described the device as life-changing after experiencing immediate relief. Similarly, Ollie, diagnosed with Functional Neurological Disorder, found that the device acted like a light switch, allowing him to regain control over daily activities like eating, sleeping, and attending school regularly.
3Clinical Trial Performance
A 2023 clinical trial involving 121 participants in the United Kingdom demonstrated an average reduction in tic frequency of 25% while using the prototype. The device has garnered attention from high-profile figures, including singer Lewis Capaldi, who tested the technology prior to a performance to manage his own Tourette's symptoms.
4Regulatory and Commercial Status
The device is currently available as a consumer wellness product under the name Neupulse-C. However, the medical-grade version, Neupulse-M, is still undergoing the formal regulatory approval process. Developers are working diligently to secure this certification, which is a necessary step for the device to be considered for official NHS adoption.
5NHS Adoption Hurdles
The National Institute for Health and Care Excellence has identified the technology as promising but requires further evidence of long-term benefits before recommending it for NHS use. The committee plans to meet in 2025 to appraise the clinical and cost-effectiveness of the device, which will inform future guidance for healthcare providers.
6Broader Therapeutic Potential
Beyond Tourette's syndrome, the underlying technology is currently being tested in early trials for individuals with Parkinson's disease to determine if it can reduce tremors. Furthermore, researchers are planning a UK-wide clinical trial to explore the device's efficacy in addressing symptoms related to anxiety and obsessive-compulsive disorder in various patients.
7Scale of the Condition
According to the charity Tourettes Action, more than 300,000 people in the United Kingdom live with Tourette's syndrome, which is currently considered an incurable condition. The device provides a non-invasive option for users, enabling them to navigate social situations, such as weddings or air travel, with significantly improved control over their movements.
8Future Research Outlook
Professor Stephen Jackson, who leads the research team, expressed that seeing the positive impact on users has been a long-held dream. The team continues to work toward regulatory approval, hoping to make the device accessible through the NHS within the next year, potentially transforming the standard of care for thousands of patients.